Last reviewed · How we verify
umeclidinium bromide and vilanterol trifenatate
umeclidinium bromide and vilanterol trifenatate is a Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | umeclidinium bromide and vilanterol trifenatate |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | M3 muscarinic receptor and beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Umeclidinium blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and causing bronchodilation. The combination provides dual bronchodilation through complementary mechanisms, improving lung function and reducing symptoms in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Nasopharyngitis
- Cough
Key clinical trials
- A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma (PHASE3)
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 (PHASE1, PHASE2)
- A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (PHASE3)
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
- Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study. (PHASE1)
- 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- umeclidinium bromide and vilanterol trifenatate CI brief — competitive landscape report
- umeclidinium bromide and vilanterol trifenatate updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about umeclidinium bromide and vilanterol trifenatate
What is umeclidinium bromide and vilanterol trifenatate?
How does umeclidinium bromide and vilanterol trifenatate work?
What is umeclidinium bromide and vilanterol trifenatate used for?
Who makes umeclidinium bromide and vilanterol trifenatate?
What drug class is umeclidinium bromide and vilanterol trifenatate in?
What development phase is umeclidinium bromide and vilanterol trifenatate in?
What are the side effects of umeclidinium bromide and vilanterol trifenatate?
What does umeclidinium bromide and vilanterol trifenatate target?
Related
- Drug class: All Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) drugs
- Target: All drugs targeting M3 muscarinic receptor and beta-2 adrenergic receptor
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Compare: umeclidinium bromide and vilanterol trifenatate vs similar drugs
- Pricing: umeclidinium bromide and vilanterol trifenatate cost, discount & access